100
Participants
Start Date
May 1, 2021
Primary Completion Date
September 30, 2023
Study Completion Date
September 30, 2023
Tenofovir Alafenamide 25 MG
All patients will receive Tenofovir Alafenamide, 25mg PO, to treat chronic hepatitis B and their previous suboptimal response over the study duration of 48 weeks. Patients will be followed every 12 weeks for medication adherence, medication refill, and follow up as per standard of care.
RECRUITING
Beijing Ditan Hospital, Capital Medical University, Beijing
RECRUITING
Shengjing Hospital of China Medical University, Shengyang
RECRUITING
Huashan Hospital Fudan University, Jing’an
RECRUITING
The First Affiliated Hospital of Bengbu Medical College, Bengbu
RECRUITING
Southwest Hospital, Chongqing
RECRUITING
Wuhan Union Hospital, Tongji Medical College (TJMC), Huazhong University of Science and Technology (HUST), Wuhan
RECRUITING
Third Affiliated Hospital of Sun Yat-sen University, Guangzhou
RECRUITING
Department of Infectious Diseases, Xi'an Jiaotong University Second Affiliated Hospital, Xi'an
RECRUITING
Liver Research Center, The First Affiliated Hospital of Fujian Medical University, Fuzhou
RECRUITING
The Third Hospital of Hebei Medical University, Hebei
Lead Sponsor
Beijing Ditan Hospital
OTHER
New Discovery LLC
INDUSTRY